Stakeholders To ‘Voice Concerns’ On Future Guidelines For Canada’s Controversial Pricing Mechanism
Executive Summary
In-person and virtual roundtables next month will let pharma companies have their say on the development of new guidelines relating to the Patented Medicine Prices Review Board’s contentious new pricing method.
You may also be interested in...
French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said.
French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said today.
Drug Candidates For NASH & Epilepsy Disorder Secure EMA PRIME Designations
The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.